Article
Topical glaucoma agent offers real IOP reduction in study
Plymouth, England—Latanoprost (Xalatan, Pfizer Ophthalmics), a potent topical ocular antihypertensive agent, does not seem to cause changes in the central corneal thickness after 2 months of follow-up. This result contradicts previous studies that reported a statistically significant decrease in the central corneal thickness, according to George D. Pappas, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
